longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

AmoyDx

300685

16.911.38% ( +0.23 )
Delay Closed: Sep 14, 15:00:00
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 19.50, below the reasonable range, cheaper than 96.91% of the time in the past 5 years, and the industry ranks 7/85, the industry Median 11.64.

19.5xP/E
¥16.91Stock price
¥0.87Earnings per share
19.5xP/E
Stock price¥16.91Earnings per share¥0.87

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
32.39x
Typical range
28.02x–44.15x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 11.64x
03876114152

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 11.64x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
688331SHRemeGen
11.44x486.37%¥66.57B
688336SHSunshine Guojian Pharmaceutical
11.64x78.00%¥35.84B
688278SHAMOYTOP
19.39x19.44%¥20.94B
300009SZANKE BIO
19.23x6.82%¥13.48B
300685SZAmoyDx
19.50x2.22%¥6.60B
603387SHGetein Biotech
15.79x--¥4.68B
688136SHSDKX
18.95x21.52%¥3.96B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.